In the January–March 2015 edition of Corporate Disputes, Group Vice President and Global Practice Leader Dr. Gregory K. Bell and other industry experts discuss managing product liability in the pharma and healthcare sector. To read the article, click the link below.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...